Given the emerging indications of ECM having multiple roles in regulating the cancer-immunity cycle [30,31], C4G and PRO-C3 may also have a predictive potential in melanoma and other cancer types treated with anti-PD-1 or anti-PD-L1 therapy. This evidence concerns the gene PDCD1 and melanoma.